Prevention of respiratory syncytial virus infection among Puerto Rican infants
P. R. health sci. j
;
21(3): 191-193, Sept. 2002.
Artigo
em Inglês
| LILACS
| ID: lil-334016
ABSTRACT
Respiratory syncytial virus (RSV) is the leading cause of lower respiratory illness in children. Prevention of this infection is available with the use of intravenous immunoglobulin or an intramuscular humanized monoclonal antibody (palivizumab). Palivizumab has been available in Puerto Rico since 1999. The objective of this study was to follow-up infants who received RSV prophylaxis with palivizumab in Puerto Rico to assess its efficacy and safety. A total of 230 infants who received RSV prophylaxis during the 2000-2001 and 2001-2002 seasons were followed-up. Adverse events from injections were minimal including erythema (2), fever (5), pain (4), and rash (2). In none of the patients prophylaxis was discontinued due to side effects. Forty-four infants (19) had at least one respiratory hospitalization throughout the season, with RSV confirmed in seven (3). Most hospitalizations occurred in the month of August when infants had received only one dose of palivizumab and on December, a peak month for RSV infections. Five infants (2.2) required admission to an intensive care unit. In none of them, RSV was confirmed. This study confirms that monthly intramuscular administration of palivizumab is effective in preventing serious RSV infections in high risk infants.
Buscar no Google
Índice:
LILACS (Américas)
Assunto principal:
Vírus Sinciciais Respiratórios
/
Infecções por Vírus Respiratório Sincicial
Tipo de estudo:
Estudo observacional
/
Estudo prognóstico
/
Fatores de risco
Limite:
Feminino
/
Humanos
/
Lactente
/
Masculino
/
Recém-Nascido
País/Região como assunto:
Caribe
/
Porto Rico
Idioma:
Inglês
Revista:
P. R. health sci. j
Assunto da revista:
Medicina
Ano de publicação:
2002
Tipo de documento:
Artigo
País de afiliação:
Porto Rico
Instituição/País de afiliação:
University of Puerto Rico/PR
Similares
MEDLINE
...
LILACS
LIS